Aktienanalyse zu Profusa Inc (PFSA)PFSAProfusa Inc

Profusa, Inc. is a digital health company developing tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its injectable and biosensors and its intelligent data platform, the Company is focused on providing people with a personalized biochemical signature. Its offering in the European Union, the Lumee Oxygen Platform, monitors tissue oxygen levels and is intended for applications such as peripheral artery disease, chronic wounds (including diabetic ulcers and pressure sores), and reconstructive surgery. Its research and development efforts are primarily focused on the Lumee Glucose Platform, a continuous glucose monitor (CGM) consisting of a biocompatible gel injected under the skin that monitors interstitial glucose levels for several months from a single injection. Its Data Discovery Platform, built on NVIDIA AI, transforms the continuous stream of biochemical sensor data into personalized clinical insights. It operates in the Healthcare sector.

Profusa Inc is not a good buy right now due to its extremely low current price of $0.93, a staggering year-to-date change of -99.88%, and a very low RSI of 17.574, indicating oversold conditions. The company is facing significant financial challenges, with a net loss of $8.8 million reported for Q2 2026 and a total stockholders' deficit of $(27.1) million. Additionally, the stock has seen a 5-day change of -34.43%, which raises concerns about its stability and future performance.